Rezolute (RZLT) Gains FDA Nod for Pre-BLA Meeting on Pancreatic Disorder Therapy
Rezolute (RZLT) received a positive regulatory update from the FDA for its therapy targeting a rare genetic disorder of the pancreas, potentially advancing it towards an official filing. The shares saw an initial jump of over 10% following the announcement.
Rezolute (RZLT) was in focus in pre-market trading on Monday after the biotech company received a positive regulatory update on its therapy for a rare genetic disorder of the pancreas, a step that could bring it closer to an official filing. RZLT shares rose more than 10% after the update.